All News
How Online Searches Reveal Patient Needs
Managing health conditions is rapidly evolving as patients increasingly turn to online resources for answers—over 65% search for health-related questions online. Our study analyzed Google search trends for rheumatic disease topics, offering a fascinating glimpse into how online search behavior can reveal patient needs and experiences. This approach, known as "infodemiology," tracks real-time Google Trends data to understand symptom- and treatment-related searches for rheumatic conditions.
Read Article![](https://pbs.twimg.com/media/Gcg8IjnWIAAbXAO.jpg)
![](https://pbs.twimg.com/media/GcX43LTXQAAVJR8.jpg)
Results from SELECT-GCA ➡️UPA 15mg + 26W GC taper demonstrates superior efficacy & reduced GC use vs PBO + 52W GC taper ➡️No new safety signals Is UPA the new kid on the block in #GCA? Ab0770 #ACRBest #ACR24 @RheumNow https://t.co/pHzozYiid5
![](https://pbs.twimg.com/media/Gcgw1IeWkAAi_mI.jpg)
![](https://pbs.twimg.com/media/GcgxKvXbAAA-w4t.jpg)
Links:
![](https://pbs.twimg.com/media/Gcf9Ip8WsAEev7a.png)
Links:
![](https://pbs.twimg.com/media/Gcg1g3-W0AAE2IS.jpg)
![](https://pbs.twimg.com/media/Gcg1izzW8AExcEW.jpg)
Links:
![](https://pbs.twimg.com/media/Gcg2ibhWMAAtRP8.jpg)
SELECT-GCA: Upa in GCA Merkel Upa 15 mg v 7.5 v PBO w slower GC taper 70% new onset, 30% relapse. Few prev on IL6 Primary endpt: sustained remission at w52- UPA 15 mg beats PBO (p=0.0019) 34% relapse in UPA vs 60% PBO Less steroids, longer time to flare @RheumNow #ACR24 #ACRBest https://t.co/1OV2889Ny0
Links:
![](https://pbs.twimg.com/media/Gcg1q2LXIAAKFxU.jpg)
Links:
![](https://pbs.twimg.com/media/GcHDi8rW8AAGFjU.jpg)
Links:
![](https://pbs.twimg.com/media/Gcgu9uRaMAQn0Pj.jpg)
![](https://pbs.twimg.com/media/GcgroDVaMAARti1.jpg)
![](https://pbs.twimg.com/media/Gcgs-TbWkAAPw8m.jpg)
![](https://pbs.twimg.com/media/GcgpU_2aMAAhpyC.png)
![](https://pbs.twimg.com/media/GcgqV09XYAAVBqM.jpg)
Links:
![](https://pbs.twimg.com/profile_images/1027501556868870145/2culK0bN_normal.jpg)
sheila RHEUMarampa ( View Tweet)
![](https://pbs.twimg.com/media/GcgnmzIaMAEhpM3.jpg)
![](https://pbs.twimg.com/media/Gcgon4DXUAAGKKF.jpg)
#ACR24 Year in Review: 💡GLP1i significantly decreased knee OA pain over time (or was it the wt loss itself?🤨) 💡CD19 CAR T-Cell therapy has potential to treat/cure many autoimmune diseases (are risks and $ worth the benefit?) 💡 High risk of CV events within 30 days of gout… https://t.co/XF63zr6lk4 https://t.co/oRNri66Il9
Links:
![](https://pbs.twimg.com/media/GcgnNHlXcAEKcZP.jpg)
Links: